Oct 28, 2026, 15:45 UTC
GSK plc reported third-quarter adjusted earnings of $1.47 per share, or 54.6 pence, while specialty-drug sales grew by double digits and vaccine sales declined.
Source:Oct 28, 2026, 12:11 UTC
GSK plc reported quarterly earnings of $1.47 per share, above the Zacks Consensus Estimate of $1.40 and compared with $1.48 per share a year earlier.
Oct 28, 2026, 11:29 UTC
GSK plc shares fell after weaker vaccine sales were reported.
Oct 26, 2026, 16:20 UTC
GSK plc unveiled initial data from a global study of a next-generation chemotherapy.
Source:Oct 26, 2026, 16:20 UTC
A GSK plc cancer drug received approval for an additional tumor type.
Source:Oct 24, 2026, 00:29 UTC
GSK plc reported that its Morez therapy achieved median progression-free survival of 11.1 months in patients with platinum-resistant ovarian cancer, with a confirmed objective response rate of 62% and median duration of response of 12.2 months in an ovarian cancer trial.
Source:Oct 21, 2026, 12:37 UTC
US regulators approved GSK plc’s hepatitis B treatment Hibsago.
Oct 21, 2026, 00:58 UTC
Hutchison MediPharma (Shanghai) expects to receive a $110 million upfront payment from a GSK plc subsidiary in the near term under the completed HMPL-A830 licensing agreement.
Source:Oct 21, 2026, 00:05 UTC
HUTCHMED (China) Ltd. announced that its subsidiary HUTCHMED (China) Ltd. and a GSK plc subsidiary completed an exclusive development and licensing agreement for HMPL-A830 outside mainland China, Hong Kong, Macau and Taiwan.
Oct 20, 2026, 20:04 UTC
The GSK plc approved GSK's hepatitis B drug, offering patients the chance to stop long-term treatment.
Source:Oct 19, 2026, 06:39 UTC
GSK plc reported early-stage trial results for risvutatug rezetecan, with confirmed responses in 11 of 18 patients at 8 mg/kg and seven of 22 patients at 6 mg/kg.
Source:Oct 18, 2026, 22:22 UTC
GSK plc reported that its B7-H3-targeted antibody-drug conjugate Ris-Rez achieved a 61% objective response rate in a lung cancer clinical trial.
Oct 15, 2026, 01:44 UTC
Chia Tai Tianqing said its strategic-cooperation product Bepirovirsen was selected for two oral presentations and eight poster presentations at the 2026 AASLD annual meeting.
Source:Oct 14, 2026, 11:38 UTC
Belgian Prime Minister Bart De Wever is set to meet GSK plc and its employees to discuss a restructuring plan.
Source:Oct 14, 2026, 08:18 UTC
GSK plc informed Belgian unions of a proposed workforce reduction expected to affect 1,217 positions, including 735 management and 482 administrative roles.
Oct 9, 2026, 18:10 UTC
GSK plc is expanding its facility in Upper Merion Township, Pennsylvania, with construction planned to begin in 2027.
Source:Oct 9, 2026, 18:09 UTC
GSK plc plans to invest more than $800 million in Pennsylvania to expand operations and create over 300 jobs.
Source:Oct 9, 2026, 12:01 UTC
Chai Discovery announced a collaboration with GSK plc following a successful wet-lab evaluation.
Source:Oct 8, 2026, 22:00 UTC
The UK government will invest £33 million through the Dame Barbara Windsor Dementia Goals programme to support dementia research and clinical-trial recruitment.
Source:Oct 8, 2026, 22:00 UTC
The UK government will announce a £48 million partnership with healthcare companies and charities to accelerate dementia research and development.
Oct 8, 2026, 11:38 UTC
GSK announced a partnership with Viola Davis to launch the “Shingles, actually” educational campaign for adults aged 50 and older.
Source:Sep 30, 2026, 11:30 UTC
GSK selected a siRNA program from Wave Life Sciences to transition to GSK for further development, triggering a milestone payment to Wave, with three additional collaboration programs advancing.
Source:Sep 28, 2026, 08:45 UTC
A vaccinology training programme was launched on September 25 in Ho Chi Minh City, Vietnam, involving 10 specialities and training units to strengthen preventive healthcare capacity.
Source:Sep 24, 2026, 12:03 UTC
GSK announced that its AZUR-1 trial met its primary endpoint, achieving meaningful sustained clinical complete response at 12 months.
Source:Sep 21, 2026, 20:15 UTC
AnaptysBio, Inc. reported its financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.
Source:Sep 21, 2026, 10:45 UTC
Virbac Animal Health India marked 20 years of operations in India, growing from a Rs 100 crore business with about 200 employees to a consolidated turnover of Rs 1,650 crore with more than 1,600 employees.
Source:Sep 15, 2026, 07:58 UTC
GSK agreed to acquire global rights to a trispecific T-cell engager from China's Chimagen Biosciences for up to $750 million, with the drug to be developed for multiple myeloma and a Phase I trial planned for 2027.
Sep 14, 2026, 05:30 UTC
GSK is providing financial sponsorship for an HKU-led study and investing in shared data infrastructure to use Greater Bay Area patient data for healthcare policy and regulatory evidence.
Source:Sep 14, 2026, 00:37 UTC
GlaxoSmithKline announced that its drug Jideytro achieved a 94% objective response rate in previously untreated ROS1-positive non-small cell lung cancer patients in the registrational Phase I/II ARROS-1 trial.
Source:Sep 10, 2026, 06:45 UTC
Japan's Ministry of Health, Labour and Welfare approved a prefilled syringe presentation of GSK's Shingrix (Recombinant Zoster Vaccine) for the prevention of shingles.
Source:Jul 28, 2026, 10:17 UTC
GSK and Hansoh Pharmaceutical announced that their experimental drug Ris-Rez met the primary endpoint of progression-free survival in a late-stage trial for bone cancer.
Source:
Page 1Next →